Arrowhead Pharmaceuticals Appoints Dr. Matt Cohen, Veteran Healthcare Investor, to Board
ARWR has more than doubled off its 52-week low of $14.3.
Summary
Arrowhead Pharmaceuticals has appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Morgan Asset Management portfolio manager, to its Board of Directors, effective June 12, 2026.
Key Events · Executive and Board Changes · ARWR
-
New Director Appointed
Dr. Matt Cohen, M.D., M.B.A., has been appointed to the Board of Directors of Arrowhead Pharmaceuticals, effective June 12, 2026.
-
Extensive Healthcare Investment Background
Dr. Cohen brings over 25 years of experience in healthcare investing and portfolio management, including serving as a Managing Director at Vida Ventures and previously as a lead growth-focused healthcare investor and portfolio manager at JP Morgan Asset Management for two decades, overseeing multi-billion-dollar funds.
-
Significant Equity Grant
In connection with his appointment, Dr. Cohen will receive a sign-on grant of restricted stock units valued at $887,000, vesting over three years, in addition to standard director compensation.
Analysis · ARWR · Life Sciences
This appointment significantly strengthens Arrowhead's Board of Directors by adding a highly experienced healthcare investor with a deep understanding of the sector and capital markets. Dr. Cohen's background as a portfolio manager for multi-billion-dollar funds at JP Morgan Asset Management and his current role at Vida Ventures suggest he will bring valuable strategic insights into capital allocation, corporate development, and investor relations. The substantial RSU grant underscores the company's commitment to attracting top-tier talent to its governance.
At the time of this filing, ARWR was trading at $76.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8B. The 52-week trading range was $14.30 to $82.26. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.